Phase I Trial of Intratumoral Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and human interferon beta (VSV-IFN-NIS), in Patients with Refractory Solid Tumors, VYRVSV2-101
|Effective start/end date||1/1/17 → 1/1/23|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.